Group 1 - The core viewpoint of the article highlights the performance of the Huatai-PineBridge Medical Services Flexible Allocation Mixed C Fund, which has shown significant returns in recent periods [1] - The fund's latest net value is 1.9690 yuan, with a weekly return of 0.66%, a three-month return of 24.86%, and a year-to-date return of 66.44% [1] - The fund was established on February 14, 2022, and as of June 30, 2025, it has a total scale of 1.069 billion yuan [1] Group 2 - The top ten stock holdings of the fund include companies such as Heng Rui Pharmaceutical, Kelun Pharmaceutical, and Hai Si Ke, with the top ten holdings accounting for a total of 68.66% of the portfolio [1]

Group 1 - The core viewpoint of the article highlights the performance of the Huatai Fuhua Medical Service Flexible Allocation Mixed C Fund, which has shown significant returns in recent periods [1] - The fund's latest net value is 1.9560 yuan, with a weekly return of 3.06%, a three-month return of 34.90%, and a year-to-date return of 65.34% [1] - The fund was established on February 14, 2022, and as of June 30, 2025, it has a total scale of 1.069 billion yuan [1] Group 2 - The top ten stock holdings of the fund include companies such as Heng Rui Pharmaceutical, Ke Lun Pharmaceutical, and Hai Si Ke, with a total holding proportion of 68.66% [1] - The fund manager is Zhang Wei, who oversees the investment strategy and portfolio management [1]

Group 1 - The core viewpoint of the article highlights the performance and holdings of the Huatai Fuhua Medical Service Flexible Allocation Mixed C Fund, which has shown significant returns since its inception [1] - The fund's latest net value is 1.8980 yuan, with a weekly return of -1.20%, a three-month return of 29.56%, and a year-to-date return of 60.44% [1] - The fund was established on February 14, 2022, and as of June 30, 2025, it has a total scale of 1.069 billion yuan [1] Group 2 - The top ten stock holdings of the fund include companies such as Heng Rui Pharmaceutical, Kelun Pharmaceutical, and Hai Si Ke, with a combined holding percentage of 68.66% [1] - The fund manager is Zhang Wei, who oversees the investment strategy and portfolio management [1]

Group 1 - The core point of the news is that the Huatai Fuhua Medical Service Flexible Allocation Mixed C fund has experienced a decline of 1.56% on June 19, with a cumulative drop of 9.38% over five consecutive trading days, and its latest net value is 1.64 yuan [1] - The fund was established in February 2022, with a total scale of 346 million yuan, and has recorded a cumulative return of -3.47% since inception [1] - As of the end of 2024, institutional investors hold 250 million shares of the fund, accounting for 97.27% of the total shares, while individual investors hold 7 million shares, accounting for 2.73% [1] Group 2 - The current fund manager, Ms. Zhang Wei, has a background in biomedical studies from Cornell University and has held various positions in the pharmaceutical research field before managing multiple funds since 2021 [2] - As of March 31, 2025, the top ten holdings of the Huatai Fuhua Medical Service Flexible Allocation Mixed C fund account for a total of 64.17%, with significant investments in companies such as Heng Rui Pharmaceutical (10.23%) and Ke Long Pharmaceutical (9.09%) [2]